Hwabao WP CSI Hong Kong Connect Medical Treatment Thematic ETF

159992

03174

09820

<p>ALPHAMAB-B (9966.HK) has seen a continuous decline after the market closed on January 20, with the overall Hong Kong biotechnology sector lacking excitement. The company has not announced any significant clinical progress or financing recently, and although trading volume slightly increased throughout the day, there was no significant action from major players, as investors' focus has shifted back to sector rotation. There are rumors in the news that the adjustment window for the medical insurance catalog is approaching, and market funds are leaning towards innovative drugs and emerging sectors, while ALPHAMAB has not shown significant movement following the hot trends. The intraday fluctuations have been mild, with no significant gathering of major players, and the buying pressure remains to be validated. On the technical side, the MACD continues to trend downward, and the 5-day moving average is providing short-term resistance, raising doubts about the sustainability of any rebound. Moving forward, attention should be paid to the substantive progress of medical insurance negotiations and the future structural rotation of the sector. If the biotechnology sector experiences another overall pullback or if the company faces unexpected negative news, short-term pressure may significantly increase. The operational suggestion is to continue observing from the right side, closely track marginal policy changes and sector movements, and wait for signals of major capital action to emerge</p>

Technical Forecast

Yinhua CSI Innovative Drugs Industry ETF

CSOP HEALTHCARE

GX CN BIOTECH-U

Yinhua CSI HK Equities Medical and Health Integration ETF

GX CN BIOTECH

Ping An CSI Medicine and Medical Device Innovation ETF

E Fund Hang Seng SCHK Innovative Drug ETF

CAM HSBIOTECH-U

Ping An CSI HK Equities Medical and Health Integration ETF

E Fund CSI HK Equities Medical and Health Integration ETF

Tianhong Hang Seng Shanghai-Shenzhen-Hong Kong Innovative Drugs Selected 50 ETF

Penghua CSI HK Connect Health Care Composite ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

CAM HSBIOTECH

Bosera Hang Seng SCHK Innovative Drug Select ETF

ALPHAMAB-B

Morning Trend | ALPHAMAB is testing the bottom with reduced volume, will the main opportunities in the pharmaceutical sector rotate?

Hwabao WP CSI Hong Kong Connect Medical Treatment Thematic ETF(159137.SZ)

Morning Trend | ALPHAMAB is testing the bottom with reduced volume, will the main opportunities in the pharmaceutical sector rotate?